Supercharge Your Innovation With Domain-Expert AI Agents!

A polysaccharide nucleic acid pharmaceutical composition for treating infantile eczema

A technology for polysaccharide nucleic acid and pediatric eczema, applied in the field of medicine, can solve the problems of heavy family burden and poor compliance of children, and achieve the effects of improving compliance, prolonging dosing interval, and improving treatment effect.

Active Publication Date: 2019-02-01
青岛市中医医院
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this therapy requires intramuscular injection at least once every other day, and the patient's compliance is poor, and the family burden is heavy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A polysaccharide nucleic acid pharmaceutical composition for treating infantile eczema
  • A polysaccharide nucleic acid pharmaceutical composition for treating infantile eczema
  • A polysaccharide nucleic acid pharmaceutical composition for treating infantile eczema

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045]

[0046]

[0047] (1) Dissolving BCG polysaccharide nucleic acid and oxymatrine in 1 ml of PBS buffer solution containing trehalose and half of Tween 80 to make an aqueous phase solution (W1);

[0048] (2) Lactide / glycolide copolymer is dissolved in 4 milliliters of dichloromethane to make oil phase solution (O);

[0049] (3) Add the above-mentioned water phase solution (W1) into the oil phase solution (O), make the two solutions stir and mix at a temperature of 25°C, a stirring speed of 8000 rpm, and a stirring time of 0.05 hours to prepare Colostrum W1 / O, stored at 4-10°C;

[0050] (4) Add the above-mentioned colostrum W1 / O into 300ml of polyvinyl alcohol under the condition of stirring at 1500 rpm, the stirring temperature is 15°C, and the stirring time is 0.2 hours to make double milk W1 / O / W2. Store at 4-10°C;

[0051] (5) Add the double emulsion W1 / O / W2 to 1% NaCl aqueous solution of 3 times the volume of the double emulsion, stir at 1500 rpm to volatilize ...

Embodiment 2

[0054]

[0055] (1) Dissolving BCG polysaccharide nucleic acid and oxymatrine in 2 ml of PBS buffer solution containing trehalose and half of Tween 80 to make an aqueous phase solution (W1);

[0056] (2) Lactide / glycolide copolymer was dissolved in 6 milliliters of dichloromethane to make oil phase solution (O);

[0057] (3) Add the above water phase solution (W1) into the oil phase solution (O), make the two solutions stir and mix at a temperature of 25°C, a stirring speed of 8000 rpm, and a stirring time of 0.2 hours to prepare Colostrum W1 / O, stored at 4-10°C;

[0058] (4) Add the above-mentioned colostrum W1 / O into 400ml of polyvinyl alcohol under the condition of stirring at 1500 rpm, the stirring temperature is 15°C, and the stirring time is 0.2 hours to make double milk W1 / O / W2. Store at 4-10°C;

[0059] (5) Add the double emulsion W1 / O / W2 into 1% NaCl aqueous solution of 4 times the volume of the double emulsion, stir at 1500 rpm to volatilize the organic solvent,...

Embodiment 3

[0061] The in vitro release test of embodiment 3 microspheres

[0062] Test sample: microspheres prepared according to the method described in Example 1-2 of the present invention.

[0063] Experimental equipment: water bath constant temperature oscillator, centrifuge.

[0064] Experimental conditions: temperature: 37±0.5°C, rotation speed: 100rpm.

[0065] Experimental method: Accurately weigh about 10 mg of the experimental sample, place it in a clear bottle with a cap of 100 ml in volume, add 90 ml of release medium (0.02% Tween-80), place it in a constant temperature oscillator in a water bath, and maintain a certain temperature and rotation speed Take samples on time.

[0066] Sampling method: extract 5ml of solution, centrifuge at 3000rpm for 10min, add 5ml of release medium, and use HPLC to detect the solution.

[0067] Sampling time points (hours): 1, 8, 16, 24, 48, 3 days, 5 days.

[0068] Test results: the microspheres prepared in Example 1 and Example 2 of the p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
cumulative release rateaaaaaaaaaa
Login to View More

Abstract

The invention relates to polysaccharide nucleic acid pharmaceutical composition for treating infantile eczema. With BCG (Bacille Calmette Guerin)-polysaccharide nucleic acid and oxymatrine as active pharmaceutical ingredients, the active pharmaceutical ingredients are prepared into slow-release microsphere preparation for injection. The preparation is prepared from BCG-polysaccharide nucleic acid, oxymatrine, lactide / glycolide copolymer, polyvinyl alcohol, tween 80 and trehalose. Through the adoption of the polysaccharide nucleic acid pharmaceutical composition for treating infantile eczema, provided by the invention, the therapeutic effect of the medicines can be collectively and efficiently expressed, the infantile eczema can be preferably treated, the treating effect can be enhanced, the pharmacy cycle can be shortened and the medication compliance can be improved.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a polysaccharide nucleic acid pharmaceutical composition for treating infantile eczema. Background technique [0002] Pediatric eczema is a kind of allergic skin disease. The etiology of eczema is complex, the most important of which is allergic factors, so children with a family history of allergies are more prone to eczema. The main reason is intolerance or allergy to ingested, inhaled or contacted substances. [0003] The main clinical features of infantile eczema are pleomorphic rash, severe itching, frequent exudation tendency, relatively symmetrical distribution, and easy recurrence. If the disease course is prolonged without timely and effective treatment, the disease may become chronic. Once suffering from eczema, it will seriously affect the child's rest, appetite and sleep, and the child's repeated scratching is also prone to secondary bacterial infection...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/715A61K35/74A61K31/4375A61K47/34A61K47/32A61K9/16A61P17/00A61P37/08
CPCA61K9/0019A61K9/5026A61K9/5031A61K9/5073A61K31/4375A61K31/715A61K35/74A61K2300/00
Inventor 潘霞
Owner 青岛市中医医院
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com